NCT03299088View on ClinicalTrials.gov

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 26, 2018

Primary Completion Date

January 28, 2021

Study Completion Date

June 25, 2024

Conditions
KRAS Gene MutationMetastatic Non-Squamous Non-Small Cell Lung CarcinomaRecurrent Non-Squamous Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
BIOLOGICAL

Pembrolizumab

Given IV

DRUG

Trametinib

Given PO

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Novartis

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Jonathan Riess

OTHER